TNDMNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
TANDEM DIABETES CARE INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$16.38+0.14 (+0.86%)
Close on Oct 19, 2026
- Market cap
- $1.13B
- P/E (TTM)
- –
- Dividend yield
- –
TANDEM DIABETES CARE INC revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| Supplies and other | $550.60M | $475.79M | $406.98M | $372.86M | – | – | – | – | 54.3% | +15.7% |
| Pump | $464.14M | $434.17M | $365.84M | $431.91M | – | – | – | – | 45.7% | +6.9% |
| Net sales recognized (deferred) for Tandem Choice program | $0 | $30.25M | -$25.11M | -$3.55M | – | – | – | – | 0.0% | -100.0% |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| United States | $706.94M | $672.69M | $554.88M | $588.77M | $524.91M | $415.68M | $302.08M | $174.19M | 69.7% | +5.1% |
| International | $307.80M | $267.52M | $192.84M | $212.45M | $177.89M | $83.15M | $60.22M | $9.68M | 30.3% | +15.1% |
From the segment and revenue-disaggregation notes of Tandem Diabetes Care's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.